LONDON, Nov. 28, 2017 /PRNewswire/ — How well does your asthma/COPD medical affairs team performance compare with the rest?
According to this latest survey of 150 pulmonologists and primary care physicians across the EU5 (UK, France, Germany, Italy and Spain) the performance of asthma/COPD medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Download the full report: https://www.reportbuyer.com/product/5214592
Use Medical Affairs Reputations: Asthma/COPD 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the 12 leading treatments for asthma/COPD from AstraZeneca, Boehringer Ingelheim, GSK, and Novartis. It shows:
• How physicians rate each team overall, and for 12 key medical affairs services.
• What is most important to physicians, plus what can be done better.
• How, and how often physicians want to meet with your team.
It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.
• Tightly bunched at the top. Five teams have leapt ahead with 78-80% of physicians recalling an interaction within the last 6 months. Where does your team sit? At the top or toward the bottom?
• Building confidence. How much do European physicians rely on medical affairs to answer questions about off-label usage? What are they spending more time talking about to medical affairs professionals than ever before?
• Fierce competition. One team has leapt to the top of the satisfaction tables for almost every medical affairs attribute. Which team is it, and what can other teams do to catch up?
• Are doctors embracing digital? Or do physicians prefer face-to-face meetings in their office or at medical conferences? And what’s the optimal frequency of these meetings?
• Good news for all. Physicians praised every drug for at least 3 areas of support provided by medical affairs.
• Information is king. 35% of respondents want to know more from their medical affairs teams. What specifically are they asking for?
Insight into Medical affairs teams for these asthma/COPD treatments
• Anoro (umeclidinium/vilanterol; GSK)
• Daxas (roflumilast; AstraZeneca)
• Eklira (aclidinium; AstraZeneca)
• Nucala (mepolizumab; GSK)
• Onbrez (indacaterol; Novartis)
• Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
• Seebri (glycopyrronium; Novartis)
• Seretide (fluticasone/salmeterol; GSK)
• Spiriva (tiotropium; Boehringer Ingelheim)
• Symbicort (budesonide/formoterol; AstraZeneca)
• Ultibro (indacaterol/glycopyrronium; Novartis)
• Xolair (omalizumab;